Jiuzhou Pharma H1 profit drops 26.33% as Q2 shows recovery signs

The CDMO company reported lower first-half revenue and earnings after Q1 order pressure, but quarter-on-quarter gains in Q2 pointed to improving client activity and a broader project pipeline.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.